SUPPORT THE WORK

GetWiki

Biogen

ARTICLE SUBJECTS
aesthetics  →
being  →
complexity  →
database  →
enterprise  →
ethics  →
fiction  →
history  →
internet  →
knowledge  →
language  →
licensing  →
linux  →
logic  →
method  →
news  →
perception  →
philosophy  →
policy  →
purpose  →
religion  →
science  →
sociology  →
software  →
truth  →
unix  →
wiki  →
ARTICLE TYPES
essay  →
feed  →
help  →
system  →
wiki  →
ARTICLE ORIGINS
critical  →
discussion  →
forked  →
imported  →
original  →
Biogen
[ temporary import ]
please note:
- the content below is remote from Wikipedia
- it has been imported raw for GetWiki








factoids
| NASDAQ-100 component| S&P 100 component| S&P 500 component}}|founded = 1978 (from merger)Kenneth Murray (biologist)>Kenneth MurrayPhillip Allen SharpWalter GilbertHeinz Schaller Charles Weissmann(Chairman)}} Michel Vounatsos {{small|(CEO)}}|industry = BiotechnologyInterferon beta-1a#Avonex>Avonex, Eloctate, 4-Aminopyridine, Obinutuzumab>Gazyva*, Interferon beta-1a#Plegridy, Rituximab>Rituxan*, Dimethyl fumarate, Natalizumab>Tysabri, Spinraza12.274 billion(2017)}}HTTPS://WWW.SEC.GOV/ARCHIVES/EDGAR/DATA/875045/000087504518000005/BIIB-20171231X10K.HTM >TITLE=BIOGEN INC. 2017 ANNUAL REPORT (FORM 10-K) PUBLISHER=U.S. SECURITIES AND EXCHANGE COMMISSION, sec.gov, 5.344 billion}} {{small|(2017)}}2.539 billion}} {{small|(2017)}}23.653 billion}} {{small|(2017)}}12.613 billion}} {{small|(2017)}}(December 2017)}}| location_city = Cambridge, Massachusetts, U.S.biogen.com}}| footnotes= *Commercialized by Genentech/Roche}}Biogen Inc. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

History

Biogen was founded in 1978 in GenevaWEB,weblink Biotech's Comeback Kid, Forbes, 2012-12-04, by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase), Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich (who contributed the first product interferon alpha). Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.In 2003, Biogen merged with San Diego, California-based IDEC Pharmaceuticals (formed in 1985 by Ivor Royston, Howard Birndorf and others) and adopted the name Biogen Idec.WEB, Biogen and IDEC Pharmaceuticals Announce Merger To Create a New Biotechnology Industry Leader,weblink IDEC — Founded in 1985 to develop monoclonal antibodies. Founders include Ivor Royston, Howard Birndorf, Richard Miller and Brook Byers, Exhibit 99.1, 1 December 2018, After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world.WEB,weblink Idec to Merge With Biogen in $6.8 Billion Deal, New York Times, 2003-06-24, Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen.WEB,weblink Biogen Drops Idec From Name, Wall Street Journal, 2015-03-23, Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB.WEB,weblink Biogen Idec Inc. Stock Quote & Summary Data, NASDAQ, In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million.WEB,weblink Biogen Idec agrees to buy Swiss company Fumapharm, PharmaTimes, 2006-06-01, www.pharmatimes.com, en, 2017-12-28, Later in the same month, the company announced its intention to acquire Fumapharm AG, consolidating ownership of Fumaderm and BG-12, an oral fumarate, which is being studied for the treatment of multiple sclerosis and psoriasis.WEB,weblink Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 Being Studied for Multiple Sclerosis, www.businesswire.com, en, 2017-12-28, In January 2007, the company announced it would acquire Syntonix Pharmaceuticals for up to $120 million, gaining Syntonix's lead product for hemophilia B as well as the technology for developing inhalable treatments.WEB,weblink Biogen to buy Syntonix in $120M deal {{!, FierceBiotech|website=www.fiercebiotech.com|language=en|access-date=2017-12-28}}WEB,weblink Biogen Idec to Acquire Syntonix, www.businesswire.com, en, 2017-12-28, In February 2013, Bloomberg broke the news that Biogen was planning to pay Elan $3.25 billion for the full rights to Tysabri, used to treat multiple sclerosis.NEWS,weblink Biogen to Pay Elan $3.25 Billion for Full Tysabri Rights, 2013-02-06, Bloomberg.com, 2017-12-28, In January 2015, the company announced that it would acquire Convergence Pharmaceuticals for up to $675 million, with the acquisition aiming to accelerate the development of Convergence's pipeline, in particular CNV1014802 – a Phase II small molecule sodium channel blocking candidate.WEB,weblink Biogen Idec Snaps Up Convergence for Up-to-$675M - GEN News Highlights - GEN, In October 2015, the company announced that it would lay off 11% of its workforce, effective immediately.WEB,weblink Biogen is cutting 11% of its workforce, In March 2019, Biogen announced it would acquire Nightstar Therapeutics for $25.50 per share ($800 million in total). Nightstar focus on adeno-associated virus based gene-therapies for inherited retinal disordersweblink With a setback in their Alzheimer's drug research, in March 2019 Biogen's shares fell sharplyweblink It ended the trial of its drug aducanumab, which it was making along with Eisaiweblink

Bioverativ

In May 2016, the company announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a public company.NEWS,weblink Biogen to spin off hemophilia drug business into a public company, Reuters, May 3, 2016, May 3, 2016, D'Souza, Savio, In August, the company announced that the spun off company would be called Bioverativ, in order to show heritage with Biogen.WEB,weblink Amid takeover chatter, Biogen introduces hemophilia spinoff Bioverativ - FiercePharma, The company would trade on the NASDAQ exchange under the ticker symbol BIVVWEB,weblink Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company {{!, Business Wire|website=www.businesswire.com|language=en|access-date=2017-12-28}}WEB,weblink Biogen unveils name for hemophilia drug spinoff: Bioverativ - The Boston Globe, and would look to be spun off in early 2017.WEB,weblink Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company - Biogen Media,

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):{hide}clade | style=font-size:90%;line-height:110% |thickness=0|label1=Biogen|1={{clade
|label1=
|1={{clade
|label1=
|1={{clade
|label1=
|1={{clade
|label1=
|1={{clade
|label1=Biogen IDEC
|1={{clade
|label1=
|1={{clade
|1=Biogen(Founded 1978)
{edih}
|label2=
|2= {hide}clade
|1= IDEC Pharmaceuticals
{edih}}}
|label2=
|2= {hide}clade
|1= Conforma Therapeutics(Acq 2006)
{edih}}}
|label2=
|2= {hide}clade
|1= Fumapharm AG(Acq 2006)
{edih}}}
|label2=
|2= {hide}clade
|1= Syntonix Pharmaceuticals(Acq 2007)
{edih}}}
|label2=
|2= {hide}clade
|1= Convergence Pharmaceuticals(Acq 2015)
{edih}}}
|label2=
|2= {hide}clade
|1= Nightstar Therapeutics(Acq 2019)
{edih}}}}}

Finances

For the fiscal year 2017, Biogen reported earnings of US$2.539 billion, with an annual revenue of US$12.274 billion, an increase of 7.2% over the previous fiscal cycle. Biogen's shares traded at over $289 per share, and its market capitalization was valued at over US$63 billion in November 2018.WEB,weblink Biogen Revenue 2006-2018 {{!, BIIB|website=www.macrotrends.net|access-date=2018-11-05}} The company ranked 245 on the 2018 Fortune 500 list of the largest United States corporations by revenue.WEB,weblink Fortune 500 Companies 2018: Who Made the List, Fortune, en-US, 2018-11-25, {| class="wikitable float-left" style="text-align: right;"!Year!Revenuein mil. USD$!Net incomein mil. USD$!Total Assetsin mil. USD$!Price per Sharein USD$!Employees|2005|2,423|161|8,382|39.89||2006|2,683|218|8,553|42.39||2007|3,172|638|8,629|52.16||2008|4,098|783|8,479|51.09||2009|4,377|970|8,552|45.11||2010|4,716|1,005|8,092|51.95||2011|5,049|1,234|9,050|84.78||2012|5,516|1,380|10,130|125.83||2013|6,932|1,862|11,863|198.43|6,850|2014|9,703|2,935|14,315|293.10|7,550|2015|10,764|3,547|19,505|324.99|7,350|2016|11,449|3,703|22,877|258.27|7,400|2017|12,274|2,539|23,653|289.19|7,300

Products

{|class="wikitable sortable"!Therapy!!Indication (In United States unless otherwise noted)!!Year Approved (US)!!Year Approved (EU)!!Additional InformationFactor IX (Recombinant), Fc Fusion Protein]>hemophilia B>|Also approved in Canada and Australia.Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX.WEB
,weblink
, Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?
, The Motley Fool
, 2014-07-04
, Avonex>AVONEX® (interferon beta-1a)Relapsing forms of multiple sclerosis1996 1997 Includes the AVONEX PEN auto-injector and the AVOSTARTGRIP titration kit approved in the U.S. in 2012.WEB
,weblink
, Avonex
, National MS Society
,
hemophilia A>|Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ELOCTATE.WEB
,weblink
, Biogen Idec's Eloctate gains FDA approval
, The Pharma Letter
, 2014-09-06
, 4-Aminopyridine>fampridine tablets)Multiple sclerosis (Walking ability)2010 2011 Marketed by Biogen in markets outside of the United States.Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by Acorda Therapeutics.WEB
,weblink
, Fampridine (Fampyra)
, MS Trust
,
Psoriasis German use >|Approved in Germany.Acquired in acquisition of Fumapharm AG in 2006.WEB
,weblink
, Biogen Idec enters deal to acquire Fumapharm
, First Word Pharma
, 2006-05-31
, obinutuzumab)>Chronic lymphocytic leukemia>|The first medicine approved with the FDA's Breakthrough Therapy Designation and is also currently in Phase 3 trials for NHL and diffuse large B-cell lymphoma.Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.WEB
,weblink
, FDA approves Gazyva for chronic lymphocytic leukemia
, FDA.gov
, 2013-01-11
, |SPINRAZA (nusinersen)|Spinal muscular atrophy|2016|2017spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.WADMANTITLE=UPDATED: FDA APPROVES DRUG THAT RESCUES BABIES WITH FATAL NEURODEGENERATIVE DISEASEDATE=23 DECEMBER 2016LAST=GRANTDATE=2016-12-27NEWSPAPER=WALL STREET JOURNALACCESS-DATE=2016-12-27, Plegridy>PLEGRIDY (peginterferon beta-1a)Relapsing forms of multiple sclerosis2014WEB
,weblink
, Biogen Idec's PLEGRIDY(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
, Reuters
, ||2014WEB
,weblink
, Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis
, The Pharma Letter
, ||
rituximab)>|Non-Hodgkin's Lymphoma (NHL)Anti-TNF Refractory Rheumatoid ArthritisANCA-Associated VasculitisChronic lymphocytic leukemia1997WEB
,weblink
, FDA Approval for Rituximab
, National Cancer Institute
,
2006WEB
,weblink
, UPDATE 1-Roche, Biogen end dispute over Rituxan follow-ons
, Reuters
, 2010-10-21
, 2011WEB
,weblink
, FDA approves Rituxan to treat two rare disorders
, FDA.gov
, 2011-04-19
, 1998 (as MabThera) The first monoclonal antibody for cancer developed by IDEC, prior to merging with Biogen.Currently commercialized by Roche and its subsidiary, Genentech.multiple sclerosis>|2013WEB
,weblink
, Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones
, The Pharma Letter
, 2007-09-03
, ||2014WEB
,weblink
, Tecifedra
, National MS Society
, ||
natalizumab)>multiple sclerosis>|Full rights purchased from partner Elan in 2013.WEB
,weblink
, Tysabri
, National MS Society
,

Pipeline

Biogen has focused its R&D efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology, hematology and immunology.Investigational MS medicines:
  • Daclizumab High-Yield Process (DAC HYP): is being developed as a potential once-monthly subcutaneous injection in the treatment of relapsing-remitting multiple sclerosis (RRMS). DAC HYP is being developed in collaboration with Abbvie, Inc. In June 2014, the companies announced positive top-line results from the Phase III DECIDE clinical trial, where DAC HYP demonstrated superiority over interferon beta-1a in annualized relapse rate.WEB


,weblink
, Once-monthly MS drug from Biogen Idec, AbbVie clears Phase III hurdle
, Fierce Biotech
, 2013-04-08
,
  • Anti-LINGO-1 (BIIB033) (Opicinumab): is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by MS, currently in Phase 2 trials.WEB


,weblink
, Lingo: a promising remyelination target in MS
, Multiple Sclerosis Research
, 2014-06-16
, Biogen has several candidates in Phase 1 and 2 clinical trials in neurodegenerative and immunological diseases including MS, neuropathic pain, spinal muscular atrophy and lupus nephritis:
  • Phase 2a: anti-LINGO-1 molecule (Opicinumab) in acute optic neuritis
  • Phase 2b: anti-TWEAK monoclonal antibody in lupus nephritis
  • Phase 2a: STX-100 in patients with idiopathic pulmonary fibrosis
  • Phase 2: Neublastin for neuropathic pain in 2013
  • Phase 1/2: BIIB067 (ISIS-SOD1Rx) for amyotrophic lateral sclerosis, in collaboration with Ionis
Biogen also has several development agreements in place with Ionis Pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders.WEB
,weblink
, Isis Pharmaceuticals and Biogen Idec
, Fierce Biotech
,
In February 2012, Biogen formalized a joint venture with Samsung, creating Samsung Bioepis. This joint venture brings Biogen's expertise and capabilities in protein engineering, cell line development, and recombinant biologics manufacturing to position the joint venture so Biogen can participate in the emerging market for biosimilars.WEB
,weblink
, Biogen Sees Eloctate FDA Delay Pushing Marketing to Mid-2014
, BusinessWeek
, 2013-12-11
, In early 2014, Biogen entered into an agreement with Eisai, Inc., to jointly develop and commercialize two of their candidates for Alzheimer's disease, which have the potential to reduce Aβ plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression.WEB
,weblink
, Isis Pharmaceuticals and Biogen Idec
, Fierce Biotech
, Biogen also has since 2015 an agreement with AGTC for the development of gene therapy for ophthalmologic diseases such as X-linked retinoschisis (XLRS) and X-linked Retinitis pigmentosa (XLRP), and up to three other genetic diseases. To this aim, Biogen paid AGTC $124 million, including an equity investment of $30 millions, and up to 1,1 billion in future milestones.Biogen Offers Up To $1 Billion for AGTC’s Ophthalmology Gene Therapy, Xconomy Boston, David Holley, July 2nd, 2015,weblink March 2019, Biogen halted Phase 3 trials of Alzheimer's disease drug Aducanumab after "an independent group's analysis show[ed] that the trials were unlikely to 'meet their primary endpoint.'"NEWS, Li, Yun, Biogen shares plunge nearly 30% after ending trial for Alzheimer's drug Aducanumab,weblink CNBC, 21 March 2019,

References

{{Reflist|2}}

External links

{{Finance links| name = Biogen| symbol = BIIB| sec_cik = BIIB| yahoo = BIIB| google = BIIB}}{{NASDAQ-100}}{{Pharmaceutical companies of the United States}}{{coord|42|21|58.3|N|71|5|13.2|W|display=title}}

- content above as imported from Wikipedia
- "Biogen" does not exist on GetWiki (yet)
- time: 4:43pm EDT - Wed, Apr 24 2019
[ this remote article is provided by Wikipedia ]
LATEST EDITS [ see all ]
GETWIKI 09 MAY 2016
GETWIKI 18 OCT 2015
M.R.M. Parrott
Biographies
GETWIKI 20 AUG 2014
GETWIKI 19 AUG 2014
GETWIKI 18 AUG 2014
Wikinfo
Culture
CONNECT